Earlier studies focused on the membrane PD-L1 (mPD-L1) as they directly interplay with PD-1, resulting in successful monoclonal antibody (mAb) inhibitors for anti-tumor immunotherapy (Figure 1C). Here, PDCD1 is linked to neoplasm.